![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Pfizer Invests $25 Million in Zentalis Pharmaceuticals
Pfizer Invests $25 Million in Zentalis Pharmaceuticals
Pfizer has acquired a $25 million stake in Zentalis Pharmaceuticals, a biopharmaceutical firm focused on developing small-molecule oncology drugs.
Zentalis will use the funding to support trials of its investigational ovarian cancer drug, ZN-c3, and its candidate B-cell lymphoma (BCL)-2 inhibitor drug, ZN-d5.
Zentalis CEO Anthony Sun said that the two companies will work together to develop the oncology treatments, but Zentalis will retain the rights to all its pipeline products.
Upcoming Events
-
18Jul
-
21Oct